ST-503 will be evaluated in a phase 1/2 trial with the first patient scheduled to receive the therapy in the coming months. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

Small fiber neuropathy (SFN) is a chronic and debilitating condition caused by damage to peripheral sensory nerves, which are responsible for pain, temperature sensation and autonomic functions.

Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy CAMBRIDGE, Mass., Sept. 16, 2021 ...

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

"Alterations in axonal membrane and channel function occur early in the disease course, prior to discernable large fibre involvement, and has the potential to be used as an early biomarker of ...